EuPFI 2025 Conference!

The European Paediatric Formulation Initiative (EuPFI) Conference 2025 on “Formulating Better Medicines for Children”, organized in partnership with the International Association for Pharmaceutical Technology (APV), took place from 16–18 September 2025 in Bordeaux, France.

The conference brought together 134 delegates from 21 countries, fostering vibrant discussions on recent innovations and global progress in paediatric medicine development. Renowned scientists delivered inspiring presentations, shedding light on the critical considerations that shape research in paediatric formulations.

EuPFI’s mission is to advance patient-centred drug products tailored for children, and this conference once again served as a dynamic platform for knowledge exchange, collaboration, and innovation. Alongside the presentations, 31 posters were showcased, providing students and early-career scientists with an invaluable opportunity to share their research, ideas, and discoveries.

We extend our heartfelt gratitude to our presenters, sponsors, exhibitors, scientific organizers, session chairs, poster judges, conference secretariat, volunteers, and to all who supported the event. A special thanks goes to our attendees, whose expertise, enthusiasm, and active engagement played a vital role in the success of the conference.

With the momentum of #EuPFI2025, we now look forward to #EuPFI2026. Stay tuned for updates on the dates and venue as we continue the journey towards advancing paediatric formulation research and developing better medicines for children.

Programme

EuPFI 2025 Programme - Click here

Sign up to our mailing list here and we will send you an email when the programme is online and keep visiting the website for conference updates in the meanwhile

Poster Presentations

Posters

ID41: Taste Assessment Study of Bivamelagon (MC72) Paediatric Solution Formulations

Amit Sawant, Quotient Sciences, United Kingdom

ID44: Unlocking Personalized Pediatric Therapies: Innovative 3D Screen Printing Technology for Age-Appropriate Drug Products

Srinivasan Shanmugam, Adare Pharma Solutions, United States

ID45: 3D-printed Pediatric Carvedilol Tablets vs a Marketed Product: A Comparison of the Performance In vitro, In vivo, and In Silico

Lidia Habtemikael, Uppsala University, Sweden

ID46: Assessing the Stability of Dopamine Neonatal Infusions: A Two-Day Simulated NICU Study

Nancy Moore SSPC, the Research Ireland Centre for Pharmaceuticals, University College Cork, School of Pharmacy, College Road, Cork, T12 YT20, Ireland

ID47: Through Their Eyes: How Patient and Public Engagement Can Shape Paediatric Formulation

Diba Keyhanfar, UCL, United Kingdom

ID48: Evaluating the Suitability of Age-Appropriate Dosage Forms: Insights into Formulation Development and Dosing Precision

Leonie-Lara Uth, Heinrich Heine University Duesseldorf, Germany

ID50: Evaluation of Age-Appropriate Dosing Strategies for Taste Masked Pellets in Infants

Karthik Neduri, Catalent Schorndorf Germany GmbH, Germany

ID51: Unique challenges in development of age-appropriate, fixed-dose combination products

Joanna Koziara, Gilead Sciences, United States

ID52:Behind the scenes of neonates, infants and toddlers' medicine design: the parental narrative

Nicole Sheena Kaneria, University College London, United Kingdom

ID54: 3D-Printed Hydroxyurea for Pediatric Use: Toward Safer and Personalized Drug Administration

Jean Laverdière, University of Montreal, Platform of Biopharmacy, Canada

ID55: Development of Bilayer Medicinal Gummies

Emilie poupin, université de bordeaux UFR de pharmacie, France

ID56: Translating EMA pip trends into faster, safer paediatric medicines: a five-year chemistry-manufacturing-controls (cmc) cross-sectional review

Alessia Menozzi, F.Hoffmann-La Roche, Switzerland

ID57: From “Undevelopable” to Pediatric-Ready: A Stabilized, Palatable Oral Solution Form of Omeprazole

Angela Simovska, Alkaloid AD North, Macedonia

ID58: Oligonucleotides and peptide therapeutics: EMA pip outcomes (2020–2025) with a chemistry-manufacturing-controls (cmc) focus

Alessia Menozzi, F.Hoffmann-La Roche, Switzerland

ID59: Rats can assess bittersweet formulations

Sejal Ranmal, senCeuTics Ltd / UCL School of Pharmacy, United Kingdom

ID62: Understanding the impact of age and prandial state on piperaquine dissolution by multivariate data analysis

Nikoletta Fotaki, University of Bath, United Kingdom

ID65: Development of a Pediatric Tablet Formulation with Chewable Consistency for SSE 3D Printing

Jonas Hoffmann, Heinrich Heine University Duesseldorf, Germany

ID66: Easy Scale-up of Wurster Processes for Pellet Drug Layering and Taste Masking

Annette Grave, Glatt Pharmaceutical Services GmbH und Co. KG, Germany

ID67: Coating monitoring of paediatric minitablets using Optical Coherence Tomography (OCT)

Rúben Martins Fraga, Research Center Pharmaceutical Engineering GmbH, Austria

ID68: Acceptability of age-appropriate furosemide orodispersible tablets (ODTs) in the paediatric population

Maisie Stephenson, Proveca Ltd, United Kingdom

ID69: Microbubble-encapsulation of actives for controlled release and its application to the taste-masking of acetaminophen

Albert Poortinga, Utrecht University, Netherlands

ID71: Children’s perspectives on the colour of oral medicines, preliminary results from an online survey

Elisa Alessandrini, University College London, School of Pharmacy, United Kingdom

ID73: From Needs to Design: Laying the Foundation for the MATE (Medication Administration Through Enteral Feeding Tubes) Database

Sifan Hu, UCL School of Pharmacy, United Kingdom

ID74: Unlocking Pharmaceutical Knowledge: AI-Enabled Structured Data Extraction

Sifan Hu, UCL School of Pharmacy, United Kingdom

ID78: Electronic tongue Evaluation of Taste-Masking Strategies for Docusate Sodium Lollipops

Xiunan Li, University College London, United Kingdom

ID79: Qualitative and quantitative sensory evaluation of primaquine granules for low-resource countries

Sejal Ranmal, UCL School of Pharmacy, University College London, United Kingdom

ID80: Acceptability of Kizfizo, a paediatric oral suspension of temozolomide for treating paediatric malignancies

Thibault VALLET, ClinSearch, France

Poster ID 2540: User perspective of minitablets for paediatric treatments in Nigeria

Poster ID 2541: User perspective of minitablets for paediatric treatments in Bangladesh

Poster ID2542: User perspective of minitablets for paediatric treatments in Brazil

Thiago Guimarães, Fundação Oswaldo Cruz, Brazil

Poster ID 2540: User perspective of minitablets for paediatric treatments in UK

Soapbox Session Presentations

Microbubble-encapsulation of actives for controlled release and its application to the taste-masking of acetaminophen
Albert Poortinga, Utrecht University, Netherlands

Acceptability of age-appropriate furosemide orodispersible tablets (ODTs) in the paediatric population
Maisie Stephenson, Proveca Ltd, United Kingdom

Through Their Eyes: How Patient and Public Engagement Can Shape Paediatric Formulation
Diba Keyhanfar, University College London School of Pharmacy, United Kingdom

From Needs to Design: Laying the Foundation for the MATE (Medication Administration Through Enteral Feeding Tubes) Database
Sifan Hu, UCL School of Pharmacy, United Kingdom

Coating monitoring of paediatric minitablets using Optical Coherence Tomography (OCT)
Rúben Martins Fraga, Research Center Pharmaceutical Engineering GmbH, Austria

Unique challenges in development of age-appropriate, fixed-dose combination products
Joanna Koziara, Gilead Sciences, United States

Session Presentations

Paediatric Drug Development: The Road we‘ve Traveled, The Future we Build
Catherine Tuleu, University College London, School of Pharmacy, United Kingdom
Carsten Timpe, Consultant, Germany

Regulatory perspectives with case studies

Minitablet regulatory perspective: lesson learned from PREVYMIS pediatric approval
Nicole Devitt Fisher, MSD, United States

Lessons learned from recent J&J Paediatric Products Marketing Applications
Aurélia Lappert, Johnson and Johnson Innovative Medicine, Belgium

Tailored Solutions for paediatric Compounding: Minitablets, Suspensions, and Orodispersible Films
Eli Dijkers, Fagron, Netherlands

Real-World Insights

Developing procedures for Paediatric Enteral Feeding tube administration of medication in a cancer hospital
Mark Klang, Memorial Sloan Kettering Cancer Center, United States

Paediatrix® Delivery System
Nicolas Micheaud, Paediatis Pharma, France

Taste matters!

Taste Strips as a Tool for Pharmaceutical Sensory Evaluation
Sejal Ranmal, UCL School of Pharmacy, United Kingdom

Bitter Molecules-TAS2R docking
Samar Issa and Jad Eid, Ecole de Biologie Industrielle, France

Non-oral

Clinical, Pharmaceutical and Industrial/Commercial Considerations for Paediatric Rectal Drug Formulations development
Tina Kauss, Université de Bordeaux, France Pascal Millet, ReMeD - Remedies and Development Network (Réseau Médicaments et Développement), France

Preconference Workshop Presentations

Beginners Workshop

Paediatric Formulation Roadmap –Points to consider & strategies to choose
Chair: David Clapham, Independent Consultant
Panel Members:
Sandra Klein, University of Greifswald
Anne-Marie Lhéritier, FRM GaleSens
Amiee Allen, IPEC
Carsten Timpe, NGT Biopharma Consultants
Catherine Tuleu, UCL School of Pharmacy
Jenny Walsh, Jenny Walsh Consulting Ltd

Advanced Workshop

Navigating Excipients Risk with Paediatric Excipient Risk Assessment (PERA) Tool

Chair: Smita Salunke, EuPFI (European Paediatric Formulation Initiative), University College London, United Kingdom
Moderators: Daniel Schaufelberger, Johns Hopkins University, School of Medicine, Schaufelberger Consulting LLC, USA;
Kevin Hughes, Colorcon, IPEC Europe, United Kingdom
Panel session: Chair: Daniel Schaufelberger, Johns Hopkins University, School of Medicine, Schaufelberger Consulting LLC, USA; Panel members:
April Braddy, U.S. Food and Drug Administration, USA
Terry Ernest, Almac Pharma Services, United Kingdom
Rachel Vogel, Sanofi, France
Philippe Tschopp, Glatt Pharmaceutical Services GmbH & Co. KG, Germany
Hidefumi Nakamura, NCCHD, Academy of Pharmaceutical Sciences and Technology, Japan
Andrea Gill, Neonatal Paediatric Pharmacists Group, United Kingdom
Smita Salunke, EuPFI (European Paediatric Formulation Initiative), University College London, United Kingdom
Kevin Hughes, Colorcon, IPEC Europe, United Kingdom

Focus Session Presentations

• The Paediatric Medicine Journey: From Priority Setting to Access for Patients
Janice Lee, Drugs for Neglected Diseases initiative (DNDi), Switzerland
Terry Ernest, Almac Pharma Services, United Kingdom

The Global Accelerator for Paediatric formulations (GAP-f): A coordinated approach to foster paediatric medicines development
Asma Hafiz, WHO Science Division, Global Accelerator for Paediatric formulations (GAP-f), Switzerland

Paediatric Drug Optimization (PADO) towards most needed formulations for children
Tiziana Masini, WHO Science Division, Global Accelerator for Paediatric formulations (GAP-f), Switzerland

WHO Target Product Profiles (TPPs) for PADO Cancer Medicines: Development and Application of a Tool to facilitate Age-Appropriate Oral Dosage Form Selection
Jenny Walsh, Jenny Walsh Consulting Ltd., United Kingdom

Innovative approaches to accelerate clinical trials in children
Tony Garcia-Prats, Wisconsin University / Stellenbosch University, United States

Accelerating optimal approval of priority formulations for antibiotic use in children
Valeria Gigante, WHO AMR Division, Switzerland

Getting optimal medicines to children: What does access really mean
Sebastien Morin, Medicines Patent Pool, Geneva

• Minitablet acceptability – Hear it from users!
Esmerald Hermans, Johnson and Johnson Innovative Medicines, Belgium
Rachel Vogel, Sanofi, France

Snapshot of global landscape on the use of minitablets for paediatric treatment
Smita Salunke, UCL School of Pharmacy, United Kingdom

Panelists
Smita Salunke, UCL School of Pharmacy, United Kingdom
Elisa Alessandrini, UCL School of Pharmacy, United Kingdom
Thiago Frances Guimaraes, Fundação Oswaldo Cruz, Brazil
Deepa Barua, ARK Foundation, Bangladesh
Chukwuebuka Emmanuel Umeyor, Nnamdi Azikiwe University, Nigeria

PCCA Award Winners

The Professional Compounding Centers of America (PCCA) sponsored three poster awards and one oral presentation award.

Winners of the poster awards:
Nancy Moore, SSPC, the Research Ireland Centre for Pharmaceuticals, University College Cork, School of Pharmacy, College Road, Cork, T12 YT20, Ireland
Assessing the Stability of Dopamine Neonatal Infusions: A Two-Day Simulated NICU Study

Jona Sandström, Heinrich Heine University Düsseldorf, Faculty of Mathematics and Natural Science, Institute of Pharmaceutics and Biopharmaceutics, Universitätsstr. 1, 40225 Düsseldorf, Germany
Evaluating the Suitability of Age-Appropriate Dosage Forms: Insights into Formulation Development and Dosing Precision

Jean Laverdière, Platform of Biopharmacy, Université de Montréal, Montreal, Canada.
3D-Printed Hydroxyurea for Pediatric Use: Toward Safer and Personalized Drug Administration

Winner of the EuPFI Young Scientist Award:
Sifan Hu, University College London, UK
Unlocking Pharmaceutical Knowledge: AI-Enabled Structured Data Extraction